Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib + Pembrolizumab in First-Line PD-L1+ R/M HNSCC
NCT06082167Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2024
- Primary completion
- Aug 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 26
01
Overview
A Phase 3 trial of zanzalintinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Exelixis, Inc.. Started Jun 2024; status: active, not recruiting.
02
Drugs
zanzalintinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06082167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082167.